FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

This trial is studying whether adding an immunotherapy drug (toripalimab) to a combination of chemotherapy delivered directly into the liver (FOLFOX-HAIC) plus a targeted therapy pill (lenvatinib) works better than the same regimen without immunotherapy for advanced liver cancer. **You may be eligible if...** - You have been diagnosed with advanced liver cancer (hepatocellular carcinoma, or HCC) - You have not received any prior cancer treatment - Your liver function is relatively well-preserved (Child-Pugh class A) - Your general health is good enough to handle treatment (ECOG score 0–2) - If you have hepatitis B, you are willing to take antiviral medication during the trial - You are 18 or older **You may NOT be eligible if...** - Your liver is failing (signs such as fluid buildup, bleeding from the gut, or confusion) - You have HIV - You have received an organ transplant - You have had significant gastrointestinal bleeding in the last 30 days - You have cancer that has spread to the brain - You have serious heart rhythm problems Talk to your doctor to see if this trial is right for you.